Literature DB >> 3140134

Adverse effect of cyclosporin on plasma cholesterol in renal transplant recipients.

A E Raine1, R Carter, J I Mann, P J Morris.   

Abstract

A prospective study of changes in plasma lipids after renal transplantation was performed in order to compare the effects of cyclosporin and conventional immunosuppression. Twenty-eight patients were studied, 18 of whom were allocated randomly to immunosuppression with either cyclosporin alone (nine subjects) or azathioprine and prednisolone (nine subjects). A further ten patients received cyclosporin and prednisolone. Total cholesterol, triglycerides and HDL, LDL and VLDL cholesterol subfractions were measured before transplantation, 21 and 90 days after transplantation, and also, in 12 patients (six on cyclosporin and prednisolone, and six on azathioprine and prednisolone), 2 years after transplantation. Triglycerides were initially elevated, and decreased after transplantation in all three groups. Total cholesterol was unchanged in the azathioprine and prednisolone group, whereas it increased significantly by 90 days in both the cyclosporin group and the cyclosporin and prednisolone group. This was due primarily to LDL cholesterol, which increased by 45% in the cyclosporin group and 28% in the cyclosporin and prednisolone group. Both total and LDL cholesterol remained elevated 2 years after transplantation in patients receiving cyclosporin and prednisolone, but were unchanged in the azathioprine and prednisolone group. There was no relationship between renal function and plasma lipid changes.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3140134     DOI: 10.1093/oxfordjournals.ndt.a091698

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  7 in total

Review 1.  Calcineurin inhibitors and post-transplant hyperlipidaemias.

Authors:  R Moore; D Hernandez; H Valantine
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

2.  Cardiovascular risk factors and diseases after renal transplantation.

Authors:  S Aker; K Ivens; B Grabensee; P Heering
Journal:  Int Urol Nephrol       Date:  1998       Impact factor: 2.370

Review 3.  The pathophysiology of Sandimmune (cyclosporine) in man and animals.

Authors:  J Mason
Journal:  Pediatr Nephrol       Date:  1990-11       Impact factor: 3.714

4.  Management of transplant renal artery stenosis.

Authors:  Dheeraj K Rajan; S William Stavropoulos; Richard D Shlansky-Goldberg
Journal:  Semin Intervent Radiol       Date:  2004-12       Impact factor: 1.513

Review 5.  Effect of immunosuppressive agents on long-term survival of renal transplant recipients: focus on the cardiovascular risk.

Authors:  Johannes M M Boots; Maarten H L Christiaans; Johannes P van Hooff
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 6.  Endocrine and metabolic abnormalities following kidney transplantation.

Authors:  W H Hörl; W Riegel; C Wanner; M Haag-Weber; P Schollmeyer; H Wieland; H Wilms
Journal:  Klin Wochenschr       Date:  1989-09-01

Review 7.  HMG CoA reductase inhibitors (statins) for kidney transplant recipients.

Authors:  Suetonia C Palmer; Sankar D Navaneethan; Jonathan C Craig; Vlado Perkovic; David W Johnson; Sagar U Nigwekar; Jorgen Hegbrant; Giovanni Fm Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2014-01-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.